| Literature DB >> 28298179 |
Michael T Bethune1, Begoña Comin-Anduix2,3, Yu-Hsien Hwang Fu4, Antoni Ribas2,3,5, David Baltimore1.
Abstract
Peptide-major histocompatibility complex (pMHC) multimers enable the detection, characterization, and isolation of antigen-specific T-cell subsets at the single-cell level via flow cytometry and fluorescence microscopy. These labeling reagents exploit a multivalent scaffold to increase the avidity of individually weak T-cell receptor (TCR)-pMHC interactions. Dextramers are an improvement over the original streptavidin-based tetramer technology because they are more multivalent, improving sensitivity for rare, low-avidity T cells, including self/tumor-reactive clones. However, commercial pMHC dextramers are expensive, and in-house production is very involved for a typical biology research laboratory. Here, we present a simple, inexpensive protocol for preparing pMHC dextramers by doping in biotinylated dextran during conventional tetramer preparation. We use these pMHC dextramers to identify patient-derived, tumor-reactive T cells. We apply the same dextran doping technique to prepare TCR dextramers and use these novel reagents to yield new insight into MHC I-mediated antigen presentation.Entities:
Keywords: T-cell receptor (TCR); biotinylated dextran; cancer immunotherapy; dextramer; immunology; ligand discovery; major histocompatibility complex (MHC); multimer; pMHC; peptide; peptide-specific MHC clustering; tetramer; tumor antigen discovery
Mesh:
Substances:
Year: 2017 PMID: 28298179 DOI: 10.2144/000114525
Source DB: PubMed Journal: Biotechniques ISSN: 0736-6205 Impact factor: 1.993